v3.26.3
Stockholders’ Equity
9 Months Ended
Sep. 30, 2026
Equity [Abstract]  
Stockholders’ Equity

Note 7. Stockholders’ Equity

 

On October 31, 2023, DSS BioHealth Securities, Inc., the Company’s largest shareholder converted 60,496,041 shares of Common Stock into 60,496,041 shares of Series A Convertible Preferred Shares, reducing its ownership of the Company’s Common Stock from approximately 88% to approximately 12%. On October 16, 2025, DSS BioHealth Security, Inc., elected to convert its 60,496,041 shares of Series A Convertible Preferred Stock into 60,496,041 shares of Impact’s Common Stock. This conversion was approved by Impact’s Board of Directors and Audit Committee.

 

The Company records stock-based payment expense related to options and warrants based on the grant date fair value in accordance with FASB ASC 718. Stock-based compensation includes expense charges for all stock-based awards to employees, directors and consultants. Such awards include option grants, warrant grants, and restricted stock awards. On October 1, 2024, 880,000 option grants with a purchase price of $3.00 per share were awarded to certain officers, directors and consultants of the Company. These options have various vesting periods, and all expire on October 31, 2031. Potential proceeds of these grants is $2,640,000 and are fair valued using a Black-Scholes model at approximately $50,000. The Company records stock-based compensation expense of approximately $2,000 for the three months ended March 31, 2025, and is included in Sales, general and administrative compensation (inclusive of stock-based compensation) on the accompanying Condensed Consolidated Statement of Operations. These options were forfeited during the fourth quarter of 2025.

 

On February 25, 2025, the Company completed the acquisition of certain assets owned by DSS Pure Air, Inc. (DSS PureAir”), a related party, for $1,150,000 to be paid by 43,189 shares of the Company’s common stock calculated on a 10-day VWAP. Assets acquired included accounts receivable, inventory and intellectual property of the Celios air purification system.

 

On February 26, 2025, the Company issued 2,887 shares of the Company’s common stock as payment of legal fees incurred associated with the Company’s initial public offering (“IPO”), registration of shares associated with its equity incentive plan as well as other related services.

 

On June 23, 2025, the Company issued 7,924 shares of the Company’s common stock as payment of legal fees incurred associated with the Company’s merger and share exchange agreement with Dr. Ashleys Limited.

 

On October 16, 2025, the Company converted its Note payable, related party to 2,531,000 shares common stock as agreed upon by the Company and DSS (lender).

 

In January 2026, the Company granted and issued 253,577 shares of Common Stock to various individuals including executives, board members, audit committee members, etc. The agreement included the individuals rescinding and cancelling any and all unexercised stock options previously granted. The Company recorded stock-based compensation expense of approximately $1,440,000 for the nine months ended September 30, 2026, and is included in Sales, general and administrative compensation (inclusive of stock-based compensation) on the accompanying Condensed Consolidated Statement of Operations

 

On November 24, 2025, the Board of Directors of Impact BioMedical approved, subject to stockholder approval, a reverse stock split of the Company’s common stock at a ratio ranging from 1-for-12.48 to 1-for-50. The reverse stock split was approved by the Company’s stockholders on December 30, 2025. On September 23, 2026, the Company effected a 1-for-12.62 reverse stock split (the “Reverse Stock Split”) of its issued and outstanding common stock, par value $0.001 per share, pursuant to an amendment to its Certificate of Incorporation filed with the Secretary of State of Nevada. The Reverse Stock Split reduced the number of issued and outstanding shares of common stock from approximately 107.8 million to approximately 8.6 million. The Reverse Stock Split did not affect the number of authorized shares, par value per share, or voting rights of the Company’s common stock. No fractional shares were issued, and any fractional shares resulting from the Reverse Stock Split were rounded up to the nearest whole share. In accordance with ASC 260-10-55-12, all historical share and per-share amounts presented in the accompanying condensed consolidated financial statements, including weighted-average shares outstanding and basic and diluted earnings (loss) per share, have been retrospectively adjusted to reflect the Reverse Stock Split for all periods presented.